Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
-
Sichuan Da Xue Xue Bao Yi Xue Ban · Nov 2014
[Preliminary study of contrast-enhanced ultrasonography in the evaluation of angiogenesis in ovarian tumors].
To investigate the role of contrast-enhanced ultrasonography (CEUS) with pulsed inversion harmonic imaging in the evaluation of angiogenesis in ovarian tumors. ⋯ The perfusion parameters PI, AUC and TTH in CEUS were correlated with MVD and VEGF in ovarian tumors, which may be useful in the evaluation of tumors angiogenesis.
-
Sichuan Da Xue Xue Bao Yi Xue Ban · Nov 2014
[Inhibition of HCN1 channels by ketamine accounts for its antidepressant actions].
To investigate the roles of hyperolarization-actived cyclic nucleotide-gated channels 1 (HCN1) in antidepressant actions of ketamine (KET). ⋯ Inhibition of HCN1 channels by ketamine accounts for its antidepressant actions.
-
Sichuan Da Xue Xue Bao Yi Xue Ban · Jul 2014
Randomized Controlled Trial[A clinical trial of ultrasound-guided facet joint block in the lumbar spine to treat facet joint related low back pain].
To determine the feasibility and clinical efficacy of ultrasound-guided facet joint injection and nerve block in lumbar facet joint for the treatment of facet-joint related low back pain. ⋯ The ultrasound-guided lumbar facet joint injection technique had a high feasibility and accuracy, and had better clinical efficacy than block blindly.
-
Sichuan Da Xue Xue Bao Yi Xue Ban · Jul 2014
[Advances in the target therapy of hematological malignancies].
With the rapid development of modern bio-medical technology, the pathogenesis of hematological malignancies including leukemia, lymphoma, myeloma has been illustrated with more and more attractive details. The diagnosis of hematological malignancies now becomes more precisely and clarified based on the progress than ever before, and the treatments of hematological malignancies keep the evolution in the way of integrating the novel molecular target drugs with conventional chemotherapy, radiotherapy, hematopoietic stem cell transplantation. The pivotal progress in the target therapy of hematological malignancies includes tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, CD20 monoclonal antibody treatment of B-cell lymphoma and CD20 positive leukemia, FLT3 inhibitors fo the treatment of FLT3 mutation positive high-risk acute myelogenous leukemia. The topics of this issue focus on the advances in this field, which reflects the new achievements in the research of hematological malignancies, and the trends of precise and stratified diagnosis as well as tailored target therapy in the future.
-
Sichuan Da Xue Xue Bao Yi Xue Ban · May 2014
Randomized Controlled Trial[Determination of dosage and effectiveness of propofol and ketamine for TIVA in adults].
To evaluate the effectiveness of combined use of propofol and ketamine for total intravenous anesthesia (TIVA) in adults and to determine their optimal doses. ⋯ Continuous pump infusion of 1 mg/(kg x h) ketamine for TIVA in adults can reduce dosage of propofol and minimize adverse effects of ketamine.